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Context: In autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an 
imperfect substitute for physiological GC secretion. Patients on long-term steroid replacement 
have increased morbidity, reduced life expectancy, and poorer quality of life.
Objective: The objective of this article is to restore adrenocortical steroidogenic function in 
recent-onset AAD.
Design: An open-label, multicenter trial of immunotherapy and trophic stimulation in new-
onset AAD was conducted. Serial measurement of serum and urine corticosteroids at baseline 
and throughout a 72-week follow-up period was performed.
Setting: This study was conducted at the endocrine departments and clinical research facilities 
at 5 UK tertiary centers.
Patients: Thirteen participants (9 female, 4 male; age 19-64 years) were included with AAD 
confirmed by high adrenocorticotropin, low circulating cortisol (basal < 100 nmol/L or post-
tetracosactide < 300 nmol/L), and positive serum 21-hydroxylase antibodies.
Intervention: All participants received dual therapy with B-lymphocyte–depleting 
immunotherapy (rituximab 1 g given twice) and repeated depot tetracosactide (1 mg on 
alternate days for 12 weeks).
Main Outcome Measure: Restoration of normal GC secretion (stimulated cortisol > 550 nmol/L) 
at week 48 was the main outcome measure.
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Results: Ten of 13 (77%) participants had detectable stimulated serum cortisol (26-265 nmol/L) 
at trial entry. Following intervention, 7 of 13 (54%) had an increase in stimulated cortisol 
measurement, with a peak response of 325 nmol/L at week 18 in 1 participant. Increased steroid 
metabolites, assayed by urine gas chromatography–mass spectrometry at week 12 and week 48, 
was detected in 8 of 13 (62%) individuals, reflecting an increase in endogenous steroidogenesis. 
Four of 13 had residual adrenal function at 72 weeks.
Conclusion: Combined treatment with rituximab and depot tetracosactide did not restore 
normal adrenal function. Nevertheless, adrenocortical plasticity is demonstrated in some 
patients, and this has the potential to be exploited to improve adrenal function. (J Clin 
Endocrinol Metab 105: 1–1, 2020)
Key Words: Addison’s disease, regenerative medicine, immunotherapy, residual adrenal 
function, steroidogenesis, adrenocorticotropin
Autoimmune Addison’s disease (AAD) is a rare disease in which immune-mediated destruction of 
steroid-producing cells in the adrenal cortex culminates 
in a potentially fatal state of steroid deficiency (1, 2). 
Steroid 21-hydroxylase and other adrenal steroidogenic 
enzymes are the target of immunological attack (3). 
Once levels of circulating glucocorticoids (GC) and 
mineralocorticoids (MC) fall to a critical state, patients 
are absolutely dependent on daily steroid replacement 
for survival.
The advent of cortisone acetate in the 1940s trans-
formed the disease from certainly fatal to a manageable 
chronic condition. Nonetheless, synthetic GCs cannot 
mimic the intrinsic diurnal rhythm of cortisol produc-
tion (4), thus current steroid replacement regimens are 
imperfect. Side effects from even a subtle excess of GC 
pose a risk to bone health, cardiovascular risk, and glu-
cose tolerance (5-10). Despite regular steroid replace-
ment, the risk of adrenal crisis remains an unpredictable 
and dangerous threat to health, and life expectancy is 
reduced in patients with AAD (11-13).
Adrenocortical plasticity has long been established (14), 
with several examples in clinical practice: patients receiving 
exogenous steroid therapy develop adrenal atrophy and 
functional adrenal failure; conversely, hypertrophy of the 
adrenal glands is seen in the setting of adrenocorticotropin 
excess (eg, Cushing’s disease). Recent early-phase studies 
of novel therapies have significantly advanced our under-
standing of the concept of residual adrenal function (RAF) 
in AAD and have suggested that adrenocortical plasti-
city may be amenable to intervention (15, 16). The use of 
B-cell–depleting immunotherapy in autoimmune disorders 
that share pathophysiological features with AAD has 
now translated to routine clinical care for some but not 
all conditions (17-19), and the first study in AAD treated 
6 newly diagnosed patients with rituximab with some 
success (15). This B-lymphocyte–depleting anti-CD20 
immunotherapy ameliorated the immunological destruc-
tion of steroid-producing cells in the adrenal gland in 
1 patient—progressively increasing concentrations of en-
dogenous GCs and MCs were seen, allowing a temporary 
complete cessation of replacement steroids (15). Thereafter, 
a second study of regenerative therapy in AAD was per-
formed: thirteen patients with established AAD of longer 
than 1 year’s duration were treated with repeated doses of 
tetracosactide (adrenocorticotropin1-24, Synacthen Depot, 
manufactured by Mallinckrodt Pharmaceuticals). This 
trophic stimulation harnessed and exploited RAF in 2 pa-
tients (4 and 8 years from diagnosis)—levels of intrinsic 
GCs and MCs increased, and both patients stopped ex-
ogenous steroids entirely (16). One patient remains off 
steroid replacement 7 years later.
These early-phase studies have greatly enhanced 
our understanding of the potential of RAF and the im-
pact regenerative medicine therapy could have in AAD. 
This paper reports on the RADS2 study, which com-
bined therapy with B-lymphocyte–depleting immuno-
therapy and trophic adrenocorticotropin stimulation 
in newly diagnosed patients for the first time, with the 
aim of harnessing and exploiting endogenous adrenal 
steroidogenesis and ultimately delivering better out-
comes for patients with this chronic disease.
Patients and Methods
Thirteen individuals (9 female, 4 male; age 19-64  years) 
with a diagnosis of new-onset AAD within the preceding 4 
weeks were recruited from endocrine or acute medical services 
in Newcastle, Exeter, Cambridge, or Cardiff, United Kingdom. 
Patients underwent robust clinical and biochemical screening 
at the point of trial entry to confirm unequivocally that adrenal 
failure was primary and of autoimmune origin. Eligibility cri-
teria included age 10 to 65 years, clinical features to confirm 
primary adrenal failure, high adrenocorticotropin (> 47 ng/L), 
low circulating cortisol concentrations (basal < 100 nmol/L or 
stimulated 30 or 60 minutes post-tetracosactide < 300 nmol/L), 
and positive serum 21-hydroxylase antibodies (21OH Abs) 
(≥  1 U/mL). A  computed tomography scan and chest x-ray 
were also performed to exclude intercurrent illness or ma-
lignancy and to assess adrenal gland appearances. Exclusion 
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criteria were significant cardiovascular or respiratory disease 
(including asthma), renal or hepatic disease, malignancy, preg-
nancy or breastfeeding, current infectious disease (including 
HIV, hepatitis B and hepatitis C, shingles/zoster, tuberculosis), 
unexplained abnormality on chest x-ray, and previous use of 
immunosuppressive or cytotoxic drugs (excluding GC).
Thirty-three potential recruits were identified and under-
went preliminary screening across 4 sites. Seventeen patients 
provided consent and were formally recruited into the 72-week 
study (Fig. 1). Of those who consented, 4 of 17 patients failed 
1 or more eligibility criteria for treatment (Fig. 2).
The study was registered at ISRCTN with ID 20220821. 
Ethical approval was granted by the National Research Ethics 
Service North East-Sunderland, reference number 12/NE/0339.
Design and intervention regimen
This open-label study of rituximab and depot tetracosactide 
followed newly diagnosed patients for 72 weeks after inter-
vention to assess for any improvement in adrenocortical 
function. The schedule of visits for screening, intervention, 
and follow-up is outlined in Fig. 1.
Rituximab (1 g by intravenous infusion) was administered 
on day 1 and day 15 of the study. Patients were taught to self-
inject 1 mg subcutaneous depot tetracosactide on day 1, and 
this was administered on alternate days for a minimum period 
of 12 weeks. In participants who had any biochemical evi-
dence of an increasing stimulated-cortisol, tetracosactide was 
continued for a maximum period of 20 weeks in total.
At recruitment, all participants were taking hydrocortisone 
as GC replacement (in doses ranging between a total of 15 
and 50 mg daily). A subset of patients had not yet commenced 
fludrocortisone, so this was started at the first clinical encounter 
with the trial team. GC replacement doses were lowered to a 
total daily dose of 10 to 15 mg hydrocortisone where possible 
to promote maximal endogenous adrenocorticotropin secre-
tion. Throughout the study, in participants with a measurable 
improvement in endogenous steroidogenesis (any increase in 
basal or stimulated-cortisol concentrations), GC replacement 
was judiciously weaned, with regular monitoring of clinical 
symptoms, blood pressure, and serum electrolytes. The lowest 
daily GC replacement dose reached was 5 mg hydrocortisone 
daily in 1 patient.
Outcome measures and assessments
The primary outcome measure was restoration of normal 
GC secretion at week 48, defined as a peak stimulated cor-
tisol of greater than 550  nmol/L. Secondary outcome 
Figure 1. Screening, treatment and monitoring schedule in the 
RADS2 study. Initial screening was performed in person or by 
telephone or email. If a patient with primary adrenal failure who was 
willing to participate in the study was identified, then formal eligibility 
testing took place. Robust clinical and biochemical assessment was 
carried out at the study entry (baseline visit), before any intervention. 
Major outcome visits (shown in middle column) were performed 
with patients “free” of exogenous steroids, allowing assessment of 
endogenous steroid production. Interim safety visits (shown in right-
hand column) allowed a shorter clinical assessment to take place, 
with the primary aim being patient safety. *Depot tetracosactide 
therapy started. One mg administered subcutaneously on alternate 
days. **Depot tetracosactide discontinued at week 12, or continued 
to a maximum of week 20, depending on response (increasing 
stimulated cortisol on week 6 and week 12 SST) and tolerability.
Figure 2. CONSORT flow diagram of patients screened, enrolled and 
treated in the RADS2 study. Thirty-three patients with adrenal failure 
diagnosed within the past 4 weeks were contacted by a member 
of the study team for discussion of the study and initial assessment 
of clinical history. Seventeen of 33 patients with primary adrenal 
failure who agreed to participate proceeded to formal consent 
and recruitment into the study. These patients were then formally 
screened to ensure they unquestionably met eligibility criteria. Four 
patients did not meet eligibility criteria on comprehensive assessment 
and could not proceed. Thirteen participants received treatment with 
rituximab and depot tetracosactide. Twelve participants completed 72 
weeks of follow-up. *Primary endpoint assessed at 48 weeks = peak 
stimulated cortisol > 550 nmol/L
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measures were restoration of normal GC secretion at weeks 
6, 12, 24, and 72, improvement of basal or peak cortisol 
(>100  nmol/L over baseline), changes of other biochemical 
parameters (dehydroepiandrosterone sulfate [DHEA-S] and 
17-hydroxyprogesterone [17OHP]), and the safety and toler-
ability of the regimen.
Participants had regular follow-up during the first 24 
weeks of the study, with clinical assessment ± biochemical as-
sessment on day 1, 7, 14, and 28 and then at 6, 12, 18, and 
24 weeks. Major outcome visits included a short Synacthen 
test (SST) and detailed serum biochemistry sampling and were 
performed at week 6, 12, 24, 48, and 72, during a 36-hour 
“steroid medication–free” window to allow assessment of en-
dogenous steroid production (Fig. 1). Overnight urine collec-
tions were performed during the steroid-free window and a 
comprehensive panel of urine steroids was measured at base-
line, week 12, and week 48. Participants underwent robust 
education and overnight hospital admission while steroid free 
to ensure safety. In the event of intercurrent illness, the visit 
was postponed for a short time; in one instance, a visit was 
canceled. Electrolytes, full blood count, lymphocyte subsets, 
and SSTs (off replacement steroids) were analyzed in real time. 
All other blood samples and urine collections were stored at 
–80°C and batch-analyzed on trial completion.
Flow cytometry analysis of B-lymphocyte subsets was 
performed on fresh material throughout the study to as-
sess the depth of B-lymphocyte depletion. CD19+ cells were 
measured at baseline and following intervention; 10  000 
lymphocyte events were counted twice at each measurement. 
Complete depletion was judged as CD19+ less than 0.1% of 
lymphocytes.
SSTs (with cortisol measured by competitive 
chemoluminescent assay, lower limit of detection[LLD] 
24  nmol/L) were performed at baseline, 6, 12, 24, 48, 
and 72, weeks and processed centrally with analysis per-
formed in real time. A  total of 250  µg soluble Synacthen 
(adrenocorticotropin1-24) was administered intramuscularly 
following a baseline blood sample drawn for cortisol meas-
urement, with further samples drawn at 30 and 60 min-
utes. Before SST, a series of serum and plasma samples were 
drawn and stored to allow batch analysis of adrenocortico-
tropin (solid-phase, chemoluminescent assay, LLD = 5 ng/L), 
dehydroepiandrosterone sulfate (DHEA-S; solid-phase com-
petitive chemoluminescent assay, LLD = 0.1 μmol/L), andro-
stenedione (solid-phase competitive chemoluminescent 
assay, LLD  =  1.05  nmol/L), aldosterone (solid-phase radio-
immunoassay, LLD  =  70 pmol/L), 17-hydroxyprogesterone 
levels (17OHP; radioimmunoassay, LLD  =  1  nmol/L), and 
21OH  Abs (enzyme-linked immunosorbent assay kit from 
RSR Ltd; positive result ≥ 1.0 U/mL) (20).
A comprehensive panel of urine steroids, collected in the 
steroid medication–free window, were measured at baseline, 
week 12, and week 48: GC precursors, GC metabolites, MC 
precursors, MC metabolites, and androgens were measured by 
gas chromatography–mass spectrometry in the laboratory at 
the Steroid Metabolome Analysis Core, Institute of Metabolism 
and Systems Research, Birmingham, UK. Thirty-two individual 
urinary steroids was quantified on an Agilent 5975 instrument 
after free and conjugated steroids were extracted from 1 mL 
of urine by solid-phase extraction (21). Urine metabolomic re-
sults were corrected for collection duration. No female patients 
were taking the oral contraceptive pill or hormone replacement 
therapy during the urine sample collections.
One major outcome visit was missed entirely because of 
illness (unsafe to stop steroid-replacement medication), and 
other safety visits were delayed by several days because of 
unavoidable commitments that participants could not re-
schedule. This was an uncontrolled exploratory study and de-
scriptive statistics are used to present outcome measurements. 
Where appropriate, continuous variables were analyzed by 
paired t tests.
Results
Participant baseline characteristics
Twelve of 13 participants (mean age 44 years; range, 
19-64 years) reported they had experienced weight loss, 
nausea or vomiting, and postural symptoms prior to 
diagnosis. Eleven of 13 reported salt craving, and all 
13 described fatigue or lethargy. Eleven of 13 were pig-
mented and 9 of 13 were in “crisis” at the point of diag-
nosis (with adrenal crisis defined as requiring hospital 
admission for parental steroids and intravenous fluids). 
Seven of 13 had concurrent autoimmune diseases (hypo-
thyroidism [n = 5], pernicious anemia [n = 2], Graves 
disease [n = 1], and premature ovarian failure [n = 1]), 
with 1 participant having a triad of autoimmune hypo-
thyroidism, pernicious anemia, and premature ovarian 
failure (Table 1).
Ten of 13 participants had detectable but subnormal 
stimulated cortisol on SST at formal screening at trial 
entry (26-265  nmol/L). All had elevated adrenocor-
ticotropin levels (68-2630  ng/L; normal range [NR] 
0-47  ng/L) and positive 21OH Abs (2.8-3648  U/mL; 
NR < 1 U/mL) (Table 1).
Adrenal steroidogenic function: serum
Seven of 13 participants demonstrated an increase in 
endogenous cortisol following intervention (an increase 
in stimulated cortisol on SST detectable during sampling 
from at least 1  major outcome visit; P  =  .45 at week 
48 vs baseline visit; paired t  test) (Fig.  3). No partici-
pants met the primary study outcome with restoration 
of normal endogenous steroidogenesis (stimulated cor-
tisol > 550 nmol/L), but 1 participant (participant 5) did 
achieve a secondary outcome measure with an increase 
in stimulated cortisol from 55 nmol/L to 155 nmol/L fol-
lowing intervention. This female patient (age 24 years) had 
clear evidence of sustained endogenous steroidogenesis 
following rituximab therapy and adrenocortical stimu-
lation. Of note, this patient had the highest titer of 
21OH Abs at trial entry (3648 U/mL) and the longest 
duration of symptoms prior to diagnosis (fatigue and 
hyperpigmentation of several years’ duration).
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Participant 4 had the highest recorded serum cortisol 
during the study—284 nmol/L post-Synacthen at week 
12 (an early morning cortisol measurement taken as 
part of safety surveillance at week 18 was 325 nmol/L). 
This 56-year-old woman retained clear evidence of en-
dogenous steroidogenesis for more than 12  months 
after trial entry.
Participant 10 did not meet any biochemical end 
points but did have noteworthy endogenous function 
throughout the study. At trial entry, his peak cortisol 
was 145 nmol/L, with a significant increase to a peak 
cortisol of 234 nmol/L at week 6. Depot tetracosactide 
was continued for 20 weeks—he retained detectable 
endogenous steroidogenesis at week 72 (peak cortisol 
114 nmol/L on stimulation). Another male patient (par-
ticipant 13)  maintained endogenous steroidogenesis 
throughout the 72-week follow-up period with a stimu-
lated cortisol at trial entry of 81 nmol/L, 127 nmol/L 
at week 48, and 116 nmol/L at week 72. At week 72, 
4 of the 13 (31%) participants had stimulated serum 
cortisol concentrations of 99  nmol/L or greater, sug-
gesting residual adrenal function. These 4 individuals 
had higher mean serum cortisol at baseline than the 
rest of the cohort (129 nmol/l vs 41 nmol/l; P =  .03) 
but were not different with regard to other baseline 
characteristics.
Measurements of DHEA-S, androstenedione, al-
dosterone, and 17OHP in serum are shown in Fig. 4. 
Aldosterone was undetectable throughout in all pa-
tients, except at baseline and at week 12 in participant 
4, who had the highest recorded stimulated cortisol in 
the study. 17OHP was higher in female participants, re-
flecting the contribution of an ovarian source. Similarly, 
serum DHEA-S concentrations were higher in men.
Adrenal steroidogenic function: urine
Eight of 13 participants demonstrated increasing 
urinary steroid metabolite excretion postintervention, 
indicating an increase in endogenous adrenal 
steroidogenesis. In these 8  individuals, we saw a 
pattern of increased GC precursor excretion, not-
ably 17-hydroxypregnanolone, pregnanetriol, and 
tetrahydro-11-deoxycortisol, during the first 12 weeks 
Table 1. Clinical and biochemical characteristics at baseline
Participant Age, y Sex
Baseline Stimulated 
Cortisol, nmol/La
Adrenocorticotropin at 
Study Entry, ng/L
21OH Antibodies at 
Study Entry, U/mL
Other Autoimmune 
Disease
1 45 F 40 1085 6.0  
2 64 F < 24 68 22.3 GD
3 36 F < 24 1050 39.6 PA
4 56 F 265 316 5.5 AH
5 24 F 55 827 3648  
6 56 F 26 915 11.6 AH
7 43 F < 24 850 71.7 AH
8 27 M 30 1054 413.3  
9 19 M 40 1542 581.7  
10 48 M 145 535 10.8  
11 60 F 45 1160 63.4 AH, PA, POF
12 39 F 88 393 17.0 AH
13 52 M 81 2630 2.8  
Thirteen treated participants. Mean age 44 years (range, 19-64 years). Stimulated cortisol on short Synacthen test at study entry ranges from less than 
24 to 265 nmol/L; peak value of 30 or 60 minutes post-tetracosactide is shown. Demographic features of those who had serum cortisol 99 nmol/L 
or greater at 72 weeks are highlighted in bold.
Abbreviations: 21OH, 21-hydroxylase; AH, autoimmune hypothyroidism; F, female; GD, Graves’ disease; M, male; NR, normal range; PA, pernicious 
anemia; POF, premature ovarian failure.
aTo convert serum cortisol values to μg/dL, divide by 27.6. Adrenocorticotropin at baseline ranged between 68 and 2630 ng/L (NR 0-47 ng/L), and all 
12 participants had positive 21OH antibodies (2.8-3648 U/mL; NR < 1 U/mL).
Figure 3. Peak stimulated cortisol on short Synacthen testing at 
baseline and major outcome visits. Peak stimulated cortisol (higher 
value of 30 or 60 minutes post-tetracosactide) at baseline (study 
entry) and at each major outcome visit: week 6, 12, 24, 48 (primary 
outcome assessment), and 72. Seven of 13 participants had an 
increase in stimulated cortisol recorded on 1 or more follow-up 
visits. Four participants (4, 6, 10, and 13) completed the study with 
a stimulated cortisol measurement of 99 nmol/L or greater. Male 
participants are shown in blue. Lower limit detection = 24 nmol/L.
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of the study in several participants, with a subsequent 
decline by week  48. Total GC metabolite produc-
tion followed a similar pattern in a smaller numbers 
of participants (4/13), with an increase in urinary 
GC excretion between baseline and week  12 (Fig.  5). 
Three participants (4, 10, and 13)  who maintained a 
peak serum cortisol greater than 100 nmol/L at week 
72 had excreted the highest amounts of GC metabol-
ites among all participants (Fig. 5). A fourth individual 
(participant 1) had significant changes in urinary steroid 
output, with increases in a range of GC precursors 
(pregnanediol, 17hydroxy-pregnanolone, pregnanetriol, 
pregnanetriolone, and tetrahydro-11-deoxycortisol). 
This increase in production of steroid precursors indi-
cates an authentic steroidogenic response to adreno-
corticotropin stimulation. Four of 13 participants had 
an increase in total MC metabolite production from 
baseline to week 12 and 5 of 13  participants had an 
increase in androgen metabolite production during 
the same period when comparing preintervention and 
postintervention. Pooling results from all the partici-
pants, there was no statistically significant increase in 
excretion of urine steroid metabolites between baseline 
and week 48.
In terms of correlation between serum and urine 
steroid response, 7 of 13 participants had a detectable 
serum response (any increase in stimulated cortisol from 
baseline), whereas 8 of 13 individuals had a detectable 
increase in urine steroid excretion (overlapping with 
6 of the serum responders). Notably, the number and 
range of increasing urinary steroid metabolites excreted 
posttreatment is not necessarily reflected in the serum 
steroid response. For example, participant 1 had only 
a small increase in peak stimulated cortisol following 
intervention (increment of 30 nmol/L in stimulated cor-
tisol measurement at week 12), but demonstrated in-
creased urinary steroid metabolite excretion across the 
spectrum including GCs, GC precursors, MCs, andro-
gens, and androgen precursors.
Immune parameters
At baseline, 21OH Ab titers ranged from 2.8 to 3648 
U/mL (positive result  ≥  1.0 U/mL). Serum immuno-
globulin M levels fell over the course of the study, but 
remained within reference range (22). Twelve of 13 
participants achieved CD19+ counts measured as 0.0 
or 0.1% of the lymphocyte population following im-
munotherapy, with counts remaining low for several 
months (minimum of 12 to a maximum of 48 depleted 
weeks). Resurgence (>  0.5% of lymphocyte popula-
tion) was detectable in all participants by the end of the 
study and occurred after a median period of 48 weeks 
(range, 12-72 weeks) (22). Participant 8 did not achieve 
complete CD19+ depletion (lowest count 0.2% at week 
6) and did not have an increase in stimulated cortisol 
following intervention.
Figure 4. Serum steroid biochemistry at baseline and major outcome visits. DHEA-S (µmol/L; solid-phase competitive chemoluminescent 
assay, lower limit detection [LLD] = 0.1 µmol/L), 17aOHP (nmol/L; radioimmunoassay, LLD = 1 nmol/L), aldosterone (pmol/L; solid-phase 
radioimmunoassay, LLD = 70 pmol/), and androstenedione (nmol/L; solid-phase competitive chemoluminescent assay, LLD = 1.05 nmol/L) were 
measured in all treated participants at each major outcome assessment (baseline, week 6, week 12, week 24, week 48, and week 72). Samples 
were collected before each major outcome visit SST, and batch analysis was performed on trial completion. Gray shading denotes LLD for each 
steroid measured. Male participants are shown in blue. Participants with the highest levels of DHEA-S are all male, likely representing a testicular 
source of DHEA-S. No patients were taking DHEA supplementation.
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Safety and tolerability
Trial medications were well tolerated by all partici-
pants. All infusions of rituximab were completed. All 
patients completed the active treatment phase; 1 of 13 
did not complete the 72-week follow-up period (at-
tended until week 48, did not attend final week 72 visit). 
Localized reactions to tetracosactide were frequently 
reported—redness, swelling, and bruising around ab-
dominal injection sites (these reactions have been pre-
viously reported with repeated doses of tetracosactide) 
(16, 23).
Four serious adverse events were recorded during 
the study; none were found to be causally related to the 
study interventions (22). Multiple adverse events were 
recorded across all sites during the study; frequently 
reported symptoms or minor illnesses were headaches, 
back pain, sore throat, and sinusitis.
Discussion
Recent early-phase experimental studies of novel ther-
apies have enabled small numbers of patients with 
AAD to wean and stop steroid replacement following 
intervention, transforming a chronic disease into a po-
tentially curable condition (15, 16, 24): This heralds an 
opportunity for a transformation in AAD management. 
The aim of this study was to combine immunotherapy 
and trophic stimulation to harness RAF, aiming to regen-
erate steroidogenic function, with the hope that depend-
ence on steroid replacement and patient outcomes could 
improve further with dual therapy. It was anticipated 
that increases in serum and urine GC postintervention 
would reflect improving endogenous steroidogenesis, 
with these biochemical changes potentially mirrored by 
enhanced quality of life indicators and fewer adrenal 
crises—ultimately less morbidity and a reduced disease 
burden for patients.
No participants met the primary study outcome of 
restoration of endogenous steroidogenesis demonstrated 
by a stimulated cortisol greater than 550 nmol/L; never-
theless, 54% (7/13) did demonstrate an increase in 
serum cortisol postintervention. The highest serum cor-
tisol midstudy was achieved by participant 4 (stimulated 
cortisol was 284 nmol/L at week 12): This allowed GC 
replacement to be weaned to 5 mg hydrocortisone per 
day for 5 months. Participant 5 achieved a secondary 
Figure 5. Urine steroid metabolite excretion (µg/24 hours) at baseline, week 12, and week 48. A comprehensive urine steroid profile was 
measured by gas chromatography–mass spectrometry at baseline, week 12 and week 48 (primary outcome assessment) of the study (see 
“Methods”). A, The sum of the metabolites of the glucocorticoid (GC) precursors (17-hydroxyprogesterone, 17-hydroxy-pregnanolone, 
pregnanetriol) and 11-deoxycortisol (tetrahydro-11-deoxycortisol) are plotted. B, The sum of the active GC metabolites (cortisol, tetrahydrocortisol, 
5α- tetrahydrocortisol, α-cortol, β-cortol, cortisone, tetrahydrocortisone, α-cortolone, and β-cortolone) are shown. C, The sum of the 
mineralocorticoid metabolites (3α,5β-tetrahydroaldosterone, tetrahydrocorticosterone, 5α-tetrahydrocorticosterone, tetrahydrodeoxycorticosterone, 
5α-tetrahydrodeoxycorticosterone, tetrahydro-11-dehydrocorticosterone, and 5α-tetrahydro-11-dehydrocorticosterone) are plotted. D, The sum of 
the androgen precursor metabolites dehydroepiandrosterone, 16α-dehydroepiandrosterone, 5-pregnanediol, and 5-pregnanetriol are plotted. E, 
The sum of the major active androgen metabolites androsterone and etiocholanolone are plotted over time. Total urine GC metabolite production 
(shown here; estimated production in µg/24 hours) increases between study entry and week 12 in 4 of 13 participants (1, 5, 12, and 13). Three of 
13 participants (4, 10, and 13) with stimulated cortisol 100 nmol/L or greater at week 72 had the highest levels of GC metabolite production in 
urine. Baseline urine samples from participant 8 and participant 10 were not available.
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outcome measure with an increase in serum cortisol 
of 100  nmol/L, and 4 others (4, 6, 10, and 13)  had 
sound biochemical evidence of maintained RAF, mani-
fest as serum cortisol of 99 nmol/l or more at 72-week 
follow-up. Although pathophysiologically interesting, 
this residual steroidogenic function is not of the mag-
nitude required to make a difference to the clinical 
well-being or hormone replacement of these patients. 
Furthermore, because there was no control group, we 
cannot exclude that the low-level persisting adrenal 
function was caused by the spontaneous natural history 
of the condition and unrelated to the trial medication.
Urine gas chromatography–mass spectrom-
etry did herald meaningful results, with 62% (8/13) 
demonstrating an increased excretion of urinary steroid 
metabolites postintervention. This pattern of urinary 
steroid excretion was variable between participants, but 
1 (participant 1)  had a demonstrable increase across 
panels of GC metabolites, GC precursors, and andro-
gens. Importantly, the increase in steroid precursor me-
tabolites unequivocally indicates improving endogenous 
adrenocortical function. Although the numbers of parti-
cipants in this study, and therefore those with a detect-
able positive response, are low, this is objective evidence 
of improving RAF many months after a proven diag-
nosis of AAD. In the previous study using adrenocor-
ticotropin1-24 stimulation (16), analysis of urine steroid 
profiles in the 2 participants who responded revealed 
that urinary excretion of GC precursors and active GC 
metabolites gradually increased from less than the fifth 
centile to greater than the median of healthy female con-
trols at 10 weeks (in 1 responder) and at 40 weeks (in a 
second responder), with a parallel increase in urine MC 
metabolite excretion. In both patients, androgen pre-
cursor and active androgen metabolite excretion was 
slower to increase.
In the present study, when urine response is com-
pared to levels of steroids detected in serum, it is ap-
parent that serum steroid measurements cannot provide 
a comprehensive illustration of endogenous gland func-
tion. Therefore, assessment of urinary steroid excretion 
should be considered the most reliable method of ana-
lysis of endogenous steroidogenesis in future studies: 
Urine steroid assays are our most valuable and robust 
tool for appraising adrenal gland function.
Around 40% of patients with AAD have never been 
hospitalized with an adrenal crisis (25, 26); perhaps a 
reduced risk of crisis might be correlated to detectable 
RAF, which will have a protective effect. The 2 partici-
pants who responded to adrenocorticotropin stimula-
tion in the previous early-phase study had never been 
hospitalized with an adrenal crisis (16). In the present 
study, participant 4 presented with a crisis (defined by 
hospital admission with requirement for parenteral ster-
oids and intravenous fluids), but participant 5 did not. 
Clearly there are insufficient data in this study to predict 
how protective RAF may be, but it does warrant fur-
ther exploration because emerging data suggest it is not 
rare among patients with established AAD (16, 27, 28). 
Furthermore, RAF has the potential to positively affect 
the risk of life-threatening crisis, alongside other mor-
bidity and mortality factors.
In healthy individuals, pulsatile adrenocorticotropin 
secretion from the pituitary starts around 3 am and 
increases to a zenith around 7 am, accompanied by a 
concordant but delayed increase in adrenal cortisol se-
cretion. As the day progresses, adrenocorticotropin pulse 
amplitude decreases, leading to reduced levels of serum 
cortisol by the late afternoon and evening: this circadian 
variation is the key to optimizing GC replacement in pa-
tients with Addison’s disease (4, 29). Exogenous steroid 
replacement cannot replicate this entirely, which is one 
of the key drivers for continuing to investigate methods 
of harnessing and exploiting endogenous steroidogenic 
capability. The presence of RAF and the fluctuating 
nature of endogenous steroidogenesis observed in this 
and previous studies reflects the heterogeneity of AAD. 
Previously, it was a widespread assumption that the in-
stigation of exogenous steroids caused adrenal glands 
to entirely cease to function. It seems probable that 
adrenocorticotropin drive diminishes rapidly following 
the start of steroid replacement in most patients, com-
pounding functional steroidogenic failure. However, 
these studies have accumulated evidence that intrinsic 
gland function can exist, even years after diagnosis, 
and has the potential to be exploited. Discovery of this 
heterogeneity is comparable to gains in knowledge in 
recent years of a spectrum of disease and a subset of pa-
tients with persisting C-peptide positivity indicative of a 
degree of maintained ß-cell function in type 1 diabetes. 
In both conditions, the disease trajectory within and be-
tween individuals is variable, resulting in greater scope 
for intervention to harness residual gland function and 
potentially improve patient outcomes—a further ex-
ample of opportunity for the development of personal-
ized medicine.
One significant challenge in detecting and monitoring 
RAF is the requirement for daily steroids in AAD. This 
limits the assessment of intrinsic gland function in a rou-
tine, outpatient clinical setting. The identification of a 
biomarker that could act as a surrogate for endogenous 
GC production would be particularly advantageous. 
Further attention should also be given to the choice of 
immunotherapy administered as rescue therapy in the 
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setting of immune-mediated adrenocortical destruction. 
Rituximab was chosen in this early-phase study because 
of its mechanism of action, efficacy in similar diseases, 
partially successful outcome in our initial study (15), and 
its durable safety record over 2 decades. Although some 
participants experienced mild side effects during admin-
istration of the drug, it was essentially well tolerated—a 
key consideration in an experimental study using a 
novel therapeutic approach. Alternative immunother-
apies, such as those that can maintain or enhance the 
activity of regulatory T  cells, may prove more robust 
for tackling diseases with immune-mediated gland de-
struction, such as type 1 diabetes (30) and AAD, but are 
likely to be less well tolerated. Consequently, they may 
not be acceptable to patients considering participation 
in early-phase studies or panels considering ethical ap-
proval. Furthermore, it is evident from this study that 
once repeated adrenocorticotropin stimulation is with-
drawn, its effect on adrenocortical steroid production 
rapidly wanes in most cases.
Conclusion
Although harnessing and exploiting RAF remains a sig-
nificant challenge, this experimental study has added 
further weight to the evidence that a sizeable propor-
tion of patients with AAD have maintained endogenous 
steroidogenic potential after diagnosis. Our under-
standing of physiological steroid production means we 
know that standard steroid replacement is an imperfect 
therapy for patients with AAD—but what does detect-
able RAF or an improvement in endogenous function 
really mean for patients? There is a wealth of evidence 
that patients with the condition exhibit increased mor-
bidity and reduced quality of life: Improved intrinsic 
gland function can be expected to counteract these 
problems to a degree, although the numbers in pilot 
clinical studies are too small to provide robust evidence 
of superior outcomes in the context of improving RAF. 
Nevertheless, there have been no trials of novel ther-
apies other than alternative steroid replacement for 
AAD for more than half a century: persisting with in-
novative therapeutic approaches is the only meaningful 
prospect for delivering a tangible improvement in the 
lives of those with the condition.
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